Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 169, Issue 5, Pages 672-682
Publisher
Wiley
Online
2015-03-03
DOI
10.1111/bjh.13338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- (2014) Michinori Ogura et al. JOURNAL OF CLINICAL ONCOLOGY
- Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma
- (2013) Takashi Ishida et al. CANCER SCIENCE
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Association between decreasing trend in the mortality of adult T-cell leukemia/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT)
- (2013) D Chihara et al. Blood Cancer Journal
- Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study
- (2012) T. Ishida et al. BLOOD
- Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
- (2012) Takashi Ishida et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
- (2012) Joannes FM Jacobs et al. LANCET ONCOLOGY
- Adult T-Cell Leukemia: A Review of Epidemiological Evidence
- (2012) Masako Iwanaga et al. Frontiers in Microbiology
- CD4+CD25+regulatory T cells in systemic sclerosis and other rheumatic diseases
- (2011) Jocea MR Michels-van Amelsfort et al. Expert Review of Clinical Immunology
- High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for Adult T cell leukemia
- (2011) Masao Ogata et al. JOURNAL OF MEDICAL VIROLOGY
- Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study
- (2010) M. Hishizawa et al. BLOOD
- Immunopathogenesis of lymphoma: Focus on CCR4
- (2010) Takashi Ishida et al. CANCER SCIENCE
- Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
- (2010) T. Ishii et al. CLINICAL CANCER RESEARCH
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
- (2010) Kazuhito Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- Array Comparative Genomic Hybridization Analysis of PTCL-U Reveals a Distinct Subgroup with Genetic Alterations Similar to Lymphoma-Type Adult T-Cell Leukemia/Lymphoma
- (2008) M. Nakagawa et al. CLINICAL CANCER RESEARCH
- Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting
- (2008) Kunihiro Tsukasaki et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started